about
Potential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza virusesReceptor-binding domain-based subunit vaccines against MERS-CoVAdvancements in the development of subunit influenza vaccinesCurrent advancements and potential strategies in the development of MERS-CoV vaccinesStructure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitorThe adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primatesYeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.MERS-CoV spike protein: a key target for antivirals.Receptor-binding domain as a target for developing SARS vaccines.Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virusReceptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread.Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development.Identification and structural characterization of a broadly neutralizing antibody targeting a novel conserved epitope on the influenza virus H5N1 hemagglutinin.Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide StrategyModulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1αA conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.Complement inhibition alleviates paraquat-induced acute lung injury.A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses.A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunityThe spike protein of SARS-CoV--a target for vaccine and therapeutic development.Research and development of universal influenza vaccines.Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus.Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design.Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.Severe acute respiratory syndrome-associated coronavirus 3a protein forms an ion channel and modulates virus release.A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccinesDifferences in the pathogenicity and inflammatory responses induced by avian influenza A/H7N9 virus infection in BALB/c and C57BL/6 mouse models.Intranasal administration of maleic anhydride-modified human serum albumin for pre-exposure prophylaxis of respiratory syncytial virus infectionPutative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4.Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection.Receptor usage and cell entry of porcine epidemic diarrhea coronavirusMulti-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus.Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.
P50
Q26825532-EDFF53CC-3D23-467F-BA78-C93568BA1835Q26851979-6B88B9C3-BC6C-4584-9638-DD50BFD043D4Q27010100-EFBAB275-9E14-42AA-B366-F80531327E71Q27012578-8D554A75-7281-45DE-A16E-14036596981AQ27689029-619E885D-5443-428A-81EF-C8C606300D9EQ28729899-4792E049-0D5A-4D0D-A4FE-84427B92D7B6Q30218075-5D24B1CB-C855-4FEA-9048-7FB64C4C06C2Q30240139-4B8B35A6-A9C6-40F9-9739-D782383A1CBCQ30353170-9A4E5034-E9E2-412E-A192-5B5A777960AAQ30359335-B311332D-61B1-49D1-87E8-7A4AC244E487Q30362113-F6CFDF1C-B835-4E51-BC62-FD6EB0070D95Q30371303-7D57CDD3-67AC-4262-92FA-3A2262B6E84DQ30384563-042BC33C-EF6B-4CE6-92BC-34488F9C4204Q30391315-CB7E352C-31B4-4156-9836-D060FA17606CQ30399700-0C4B3271-2C2F-4326-8E34-E5EE1A223CD3Q30432264-59E3652F-9921-4935-B045-E28717B1837DQ30432706-631AB76B-278F-4A0A-975E-7C614C363A16Q30535722-AC867D0F-51B4-4D4A-93AB-51C9A6D235D9Q30661709-6D04EEA7-CCAA-4C2C-8639-186917476AA0Q33698542-D3456FE0-989A-4F21-B431-B72756992A47Q33743790-61E55FA7-725B-4F35-8A98-444AE3E50DA7Q33769308-BE6BD721-0E77-4F52-97EA-B2FA5CDEAABBQ33815195-19E5418D-0C91-4C44-8F51-F614F1AD5EB0Q33904997-4D914ACA-6B52-413E-BA59-8BF079377A2AQ34015988-A2DB4C76-D5AD-403F-9BDB-8479176C2972Q34093195-C768BE44-4166-45F8-BBC4-69D9E592D255Q34120263-1E3B0B29-6F17-4897-A83A-A5377DA80CFFQ34324907-BAD3543F-C576-4C9C-8431-DC9B406E5A80Q34332142-4BBCCEF4-2ED0-4E21-9C24-28BFB5BFEAFAQ34548282-352C8263-42D3-47DB-A8CC-FDF5DFFF03CBQ35033777-625209B3-D204-4E91-BB96-934BCDAF8FF0Q35063993-860688D8-1CA4-442E-81E7-A18377D4C2DCQ35133823-2587EBA6-4083-44DC-BA6C-A58FB9ADAB8DQ35160026-FFDCBF29-4DF7-45D4-B379-52C1B1A5C9EDQ35163604-A081AB7D-F2F6-4661-B7B6-F2A4807DD819Q35392075-F740FD1B-911E-4EBF-9466-35DA9802D272Q35641223-9A3E5B5B-F128-40D9-B5E3-AC3C207594A8Q35877765-136C3BAF-93FF-4C0E-863B-14F6881A85ABQ35886473-57681FBB-219A-4FC6-9F0E-B91BDDF70E8BQ35887235-95FE9B41-BA7B-409B-8121-6739600FED59
P50
name
Lanying Du
@en
type
label
Lanying Du
@en
prefLabel
Lanying Du
@en